Comunicate ale companiilor · 13.11.20261 min read
Leqembi® Pen subcutaneous treatment launched in Japan
Traducere automată locală · Limba originală a sursei
Summary
STOCKHOLM, Nov. 13, 2026 — BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today announced that Leqembi Pen, the subcutaneous formulation of lecanemab, has been launched in Japan for the…
Limba originală a sursei: PR Newswire UK — News ReleasesDeschide comunicatul original →